Please use this identifier to cite or link to this item: https://doi.org/10.3390/biomedicines9121776
Title: Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease
Authors: Bhave, Sayali 
Ho, Han Kiat 
Keywords: non-alcoholic fatty liver diseases
receptor tyrosine kinases
steatosis
fibrosis
EGFR
c-MET
AXL
FGFR
VEGFR
Issue Date: 1-Dec-2021
Publisher: MDPI
Citation: Bhave, Sayali, Ho, Han Kiat (2021-12-01). Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. BIOMEDICINES 9 (12). ScholarBank@NUS Repository. https://doi.org/10.3390/biomedicines9121776
Abstract: Recently, non-alcoholic fatty liver disease (NAFLD) has emerged as a predominant health concern affecting approximately a quarter of the world’s population. NAFLD is a spectrum of liver ailments arising from nascent lipid accumulation and leading to inflammation, fibrosis or even carcinogenesis. Despite its prevalence and severity, no targeted pharmacological intervention is approved to date. Thus, it is imperative to identify suitable drug targets critical to the development and progression of NAFLD. In this quest, a ray of hope is nestled within a group of proteins, receptor tyrosine kinases (RTKs), as targets to contain or even reverse NAFLD. RTKs control numerous vital biological processes and their selective expression and activity in specific diseases have rendered them useful as drug targets. In this review, we discuss the recent advancements in characterizing the role of RTKs in NAFLD progression and qualify their suitability as pharmacological targets. Available data suggests inhibition of Epidermal Growth Factor Receptor, AXL, Fibroblast Growth Factor Receptor 4 and Vascular Endothelial Growth Factor Receptor, and activation of cellular mesenchymal-epithelial transition factor and Fibroblast Growth Factor Receptor 1 could pave the way for novel NAFLD therapeutics. Thus, it is important to characterize these RTKs for target validation and proof-of-concept through clinical trials.
Source Title: BIOMEDICINES
URI: https://scholarbank.nus.edu.sg/handle/10635/227177
ISSN: 2227-9059
DOI: 10.3390/biomedicines9121776
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
Exploring the Gamut of Receptor Tyrosine Kinases for Their Promise in the Management of Non-Alcoholic Fatty Liver Disease. .pdf713.24 kBAdobe PDF

OPEN

PublishedView/Download

Page view(s)

33
checked on Sep 22, 2022

Download(s)

1
checked on Sep 22, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.